eFFECTOR Therapeutics is driven by science, and we are committed to developing safe and effective therapies for patients. Our goal is to provide our novel treatments to patients as quickly as possible, but in a way that stands up to scientific rigor and achieves the best clinical outcomes.
Our clinical programs are designed to answer important scientific questions about the potential risks and benefits of our product candidates, and to provide data to support regulatory approval. Patients are required to meet specific eligibility criteria to enter our clinical trials, and not every patient will meet eligibility criteria. When a patient does not meet the eligibility criteria for a clinical trial, or if a clinical trial is not available, and the patient has exhausted available treatment options, companies may consider providing access to its investigational medicines outside of a clinical trial through a process called Expanded Access.
eFFECTOR has determined that Expanded Access cannot currently be offered for any of its product candidates and the company does not currently provide its product candidates outside of enrollment in clinical trials.
If you have questions regarding this policy or any of our ongoing clinical trials, please contact: clinicaltrials@eFFECTOR.com